Qnovias’s Tobacco Withdrawal Treatment Shows Promising Results in Initial Study

Qnovia, a pharmaceutical and medtech business, has released encouraging findings from the early stages of medical research for their inhaled smoking withdrawal treatment.

The pharmaceutical, labelled QN-01, is being assessed separately in the United States and the United Kingdom. In the US, this falls under the FDA and in the UK, it falls under the Medicines and Healthcare Products Regulatory Agency.

While initiatives have been pushed by medical professionals about the risks associated with smoking tobacco, smoking-related illnesses still take nearly half a million lives in the US annually.

Conventional therapies fall short and are unable to provide nicotine promptly during peak phases, which is essential when attempting to reduce the effects of withdrawal.

When assessed alongside other nicotine replacement therapies, QN-01 showed “exceptional” interaction, absorption, and distribution in the body.

Head of technology at Qnovia, Mario Danek, commented, “This data demonstrates our device has significant potential in bringing new hope to smokers who want to quit smoking.”

The leading executive of Qnovia, Brian Quigley, stated, “We believe our nicotine delivery platform could be a game-changer in alleviating cravings and withdrawal symptoms for those smokers who need it most.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.